First quarter revenues of $2.37 billion, up 1.5% from 2023 First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023 Full year 2024 revenues now expected to be between $9.40 billion and $9.48 billion; reported diluted EPS now expected to be between $7.57 and $7.82; and adjusted diluted EPS expected to be between $8.72 and $8.97 SECAUCUS, N.J., April 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leadin ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Quest Diagnostics (DGX) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 23. ...

Quest Diagnostics (DGX) is set to release first-quarter 2024 results on Apr 23 before the opening bell.The company posted adjusted earnings per share (EPS) of $2.15 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 0.47%. Quest Diagnostics beat earnings estimates in each of the trailing four quarters, the average surprise being 2.13%.Let’s look at how things have shaped up before this announcement.Factors at PlayBase BusinessIn the first quarter of 2024, the company is likely to ...

Quest Diagnostics Incorporated (DGX) entered into a research collaboration with Broad Clinical Labs — the expert in whole genome sequencing (WGS). The collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.For investors’ note, Broad Clinical Labs is a pioneer in human whole genome sequencing, having sequenced more than 600,000 genomes as part of its aim to expedite the knowledge and diagnosis of human disease.M ...

SECAUCUS, N.J., March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.   The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode ...

Quest Diagnostics, Incorporated (DGX) recently collaborated with Instacart to improve both food access and healthy eating habits for underserved communities across the United States. To reduce the impact of social determinants of health on care — Pack Health, a Quest Diagnostics company — is offering grocery delivery services via Instacart to those enrolled in its coaching programs.Through this collaboration, both companies are offering user-friendly solutions that leverage Instacart's reach, scale, selecti ...

SECAUCUS, N.J., Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m. Eastern Time.The fireside chat and Q&A session will be webcast live ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-12215 Quest Diagnostics Incorporated 500 Plaza Drive Secaucus, NJ 07094 (973) 520-2700 Delaware 16-1387862 ...

Quest Diagnostics (DGX) recently introduced a highly advanced predictive gene expression test, MelaNodal Predict, to help personalize treatment decisions for patients with melanoma.  The lab-developed test is based on the technology developed by the biotechnology company, SkylineDx, alongside Mayo Clinic and has been validated by DGX.The latest development will strongly fortify the company’s oncology test offering across the advanced diagnostics spectrum. Dermatologists and other providers nationwide can be ...

–  Roche led the financing alongside existing and new investors –  – The funds will progress clinical programs and expand platform capabilities – SOUTH SAN FRANCISCO, Calif., Feb. 15, 2024 /PRNewswire/ -- Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors. The funding enables Freenome to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platfor ...